The topoisomerase i inhibitors market size has grown strongly in recent years. It will grow from $5.46 billion in 2025 to $5.79 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to limited availability of topoisomerase i inhibitors, reliance on camptothecin derivatives, growing cancer prevalence, increasing hospital oncology services, slow development of non-camptothecin compounds.
The topoisomerase i inhibitors market size is expected to see strong growth in the next few years. It will grow to $7.31 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to development of non-camptothecin inhibitors like lmp-400 and indenoisoquinolines, rising oral and injectable formulations, expansion of oncology research and clinical trials, increasing regulatory approvals and faster drug commercialization, integration of personalized medicine and targeted therapies. Major trends in the forecast period include rising adoption of topoisomerase i inhibitors in oncology, expansion of injectable and oral chemotherapy formulations, increasing clinical trials and research activities, focus on personalized and targeted cancer therapies, growing hospital and clinic demand for novel anticancer agents.
The growing prevalence of cancer is expected to significantly boost the topoisomerase I inhibitors market in the near future. Cancer, a group of diseases defined by the uncontrolled growth and spread of abnormal cells, can result in serious health complications, including death. The rise in cancer cases is linked to increasing lifestyle-related risk factors such as poor diet, insufficient physical activity, and tobacco use, all contributing to higher cancer incidence. Topoisomerase I inhibitors are used in cancer treatment by disrupting the DNA replication process in cancer cells, causing DNA damage that halts cell division and induces cell death. For example, in February 2024, the World Health Organization (WHO) projected that by 2050, over 35 million new cancer cases will be diagnosed, a 77% increase from the 20 million expected in 2022. This surge in cancer cases will be a key driver for the growth of the topoisomerase I inhibitors market.
Leading companies in the topoisomerase I inhibitors market are concentrating on developing advanced treatments such as antibody-drug conjugates (ADCs) to overcome drug resistance by leveraging the targeting capabilities of antibodies. ADCs are specialized cancer therapies that attach antibodies to cytotoxic drugs, ensuring that the drug is delivered directly to cancer cells while minimizing damage to healthy tissue. For instance, in July 2024, Zymeworks Inc., a biotechnology company based in Canada, announced that the U.S. Food and Drug Administration (FDA) approved its investigational new drug (IND) application for ZW191. This innovative ADC targets the folate receptor-α (FRα) and delivers a topoisomerase I inhibitor (TOPO1i). ZW191 was developed using the company’s proprietary drug conjugate platforms, incorporating the advanced TOPO1i-based payload technology, ZD06519. It primarily targets FR⍺-expressing tumors, including ovarian and other gynecological cancers, as well as non-small cell lung cancer (NSCLC). The drug was designed with eight drug-antibody ratios (DAR) to optimize safety and efficacy, aiming for a balance of tolerability and therapeutic benefit.
In May 2024, Genmab A/S, a biotechnology company based in Denmark, acquired ProfoundBio for $1.8 billion. This acquisition bolstered Genmab's position in the targeted cancer therapy market, with a particular focus on ovarian and other solid tumors. This move aligns with Genmab’s strategy to expand its portfolio of innovative cancer treatments. ProfoundBio, a U.S.-based company, specializes in the manufacturing of topoisomerase I inhibitors.
Major companies operating in the topoisomerase i inhibitors market are Pfizer Inc, AstraZeneca PLC, Novartis AG, Merck KGaA, Daiichi Sankyo Company Limited, Ipsen Pharma SAS, Fresenius Kabi AG, Debiopharm Group SA, Sigma Tau Industrie Farmaceutiche Riunite SPA, Sagent Pharmaceuticals Inc, Gibson Oncology LLC, TopoGEN Inc, DualityBio Inc, Iksuda Therapeutics Ltd, Nektar Therapeutics, Exelixis Inc, BeiGene Ltd, Takeda Pharmaceutical Company Limited, Amgen Inc, Hutchmed China Limited.
North America was the largest region in the topoisomerase I inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the topoisomerase i inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the topoisomerase i inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the topoisomerase i inhibitors market by increasing costs for imported active pharmaceutical ingredients (apis) and formulation equipment. Segments such as camptothecin derivatives and novel non-camptothecin inhibitors are particularly impacted, with Asia-Pacific regions like china and india facing higher import duties. This has led to higher production costs and supply chain complexities. On the positive side, tariffs have encouraged local manufacturing, research collaborations, and investment in domestic drug production capabilities.
The topoisomerase i inhibitors market research report is one of a series of new reports that provides topoisomerase i inhibitors market statistics, including topoisomerase i inhibitors industry global market size, regional shares, competitors with a topoisomerase i inhibitors market share, detailed topoisomerase i inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the topoisomerase i inhibitors industry. This topoisomerase i inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Topoisomerase I inhibitors are a class of therapeutic agents that interfere with the activity of topoisomerase I, an enzyme responsible for relieving the torsional strain that occurs during DNA replication and transcription. These inhibitors work by binding to the enzyme-DNA complex, preventing the re-ligation of DNA strands after the enzyme induces a temporary break. Disruption of topoisomerase I activity leads to the accumulation of DNA damage, ultimately resulting in cell death, particularly in rapidly dividing cells.
The main types of topoisomerase I inhibitors include camptothecin derivatives and non-camptothecin-based inhibitors. Camptothecin derivatives are drugs developed from camptothecin, a natural compound extracted from the Chinese tree Camptotheca acuminata. These inhibitors can be administered through oral, injectable, and other routes and are commonly used in hospitals, clinics, and other healthcare settings.
The topoisomerase I inhibitors market consists of sales of chemotherapy drugs, diagnostic kits, intravenous infusion bags and combination therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The topoisomerase i inhibitors market size is expected to see strong growth in the next few years. It will grow to $7.31 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to development of non-camptothecin inhibitors like lmp-400 and indenoisoquinolines, rising oral and injectable formulations, expansion of oncology research and clinical trials, increasing regulatory approvals and faster drug commercialization, integration of personalized medicine and targeted therapies. Major trends in the forecast period include rising adoption of topoisomerase i inhibitors in oncology, expansion of injectable and oral chemotherapy formulations, increasing clinical trials and research activities, focus on personalized and targeted cancer therapies, growing hospital and clinic demand for novel anticancer agents.
The growing prevalence of cancer is expected to significantly boost the topoisomerase I inhibitors market in the near future. Cancer, a group of diseases defined by the uncontrolled growth and spread of abnormal cells, can result in serious health complications, including death. The rise in cancer cases is linked to increasing lifestyle-related risk factors such as poor diet, insufficient physical activity, and tobacco use, all contributing to higher cancer incidence. Topoisomerase I inhibitors are used in cancer treatment by disrupting the DNA replication process in cancer cells, causing DNA damage that halts cell division and induces cell death. For example, in February 2024, the World Health Organization (WHO) projected that by 2050, over 35 million new cancer cases will be diagnosed, a 77% increase from the 20 million expected in 2022. This surge in cancer cases will be a key driver for the growth of the topoisomerase I inhibitors market.
Leading companies in the topoisomerase I inhibitors market are concentrating on developing advanced treatments such as antibody-drug conjugates (ADCs) to overcome drug resistance by leveraging the targeting capabilities of antibodies. ADCs are specialized cancer therapies that attach antibodies to cytotoxic drugs, ensuring that the drug is delivered directly to cancer cells while minimizing damage to healthy tissue. For instance, in July 2024, Zymeworks Inc., a biotechnology company based in Canada, announced that the U.S. Food and Drug Administration (FDA) approved its investigational new drug (IND) application for ZW191. This innovative ADC targets the folate receptor-α (FRα) and delivers a topoisomerase I inhibitor (TOPO1i). ZW191 was developed using the company’s proprietary drug conjugate platforms, incorporating the advanced TOPO1i-based payload technology, ZD06519. It primarily targets FR⍺-expressing tumors, including ovarian and other gynecological cancers, as well as non-small cell lung cancer (NSCLC). The drug was designed with eight drug-antibody ratios (DAR) to optimize safety and efficacy, aiming for a balance of tolerability and therapeutic benefit.
In May 2024, Genmab A/S, a biotechnology company based in Denmark, acquired ProfoundBio for $1.8 billion. This acquisition bolstered Genmab's position in the targeted cancer therapy market, with a particular focus on ovarian and other solid tumors. This move aligns with Genmab’s strategy to expand its portfolio of innovative cancer treatments. ProfoundBio, a U.S.-based company, specializes in the manufacturing of topoisomerase I inhibitors.
Major companies operating in the topoisomerase i inhibitors market are Pfizer Inc, AstraZeneca PLC, Novartis AG, Merck KGaA, Daiichi Sankyo Company Limited, Ipsen Pharma SAS, Fresenius Kabi AG, Debiopharm Group SA, Sigma Tau Industrie Farmaceutiche Riunite SPA, Sagent Pharmaceuticals Inc, Gibson Oncology LLC, TopoGEN Inc, DualityBio Inc, Iksuda Therapeutics Ltd, Nektar Therapeutics, Exelixis Inc, BeiGene Ltd, Takeda Pharmaceutical Company Limited, Amgen Inc, Hutchmed China Limited.
North America was the largest region in the topoisomerase I inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the topoisomerase i inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the topoisomerase i inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the topoisomerase i inhibitors market by increasing costs for imported active pharmaceutical ingredients (apis) and formulation equipment. Segments such as camptothecin derivatives and novel non-camptothecin inhibitors are particularly impacted, with Asia-Pacific regions like china and india facing higher import duties. This has led to higher production costs and supply chain complexities. On the positive side, tariffs have encouraged local manufacturing, research collaborations, and investment in domestic drug production capabilities.
The topoisomerase i inhibitors market research report is one of a series of new reports that provides topoisomerase i inhibitors market statistics, including topoisomerase i inhibitors industry global market size, regional shares, competitors with a topoisomerase i inhibitors market share, detailed topoisomerase i inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the topoisomerase i inhibitors industry. This topoisomerase i inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Topoisomerase I inhibitors are a class of therapeutic agents that interfere with the activity of topoisomerase I, an enzyme responsible for relieving the torsional strain that occurs during DNA replication and transcription. These inhibitors work by binding to the enzyme-DNA complex, preventing the re-ligation of DNA strands after the enzyme induces a temporary break. Disruption of topoisomerase I activity leads to the accumulation of DNA damage, ultimately resulting in cell death, particularly in rapidly dividing cells.
The main types of topoisomerase I inhibitors include camptothecin derivatives and non-camptothecin-based inhibitors. Camptothecin derivatives are drugs developed from camptothecin, a natural compound extracted from the Chinese tree Camptotheca acuminata. These inhibitors can be administered through oral, injectable, and other routes and are commonly used in hospitals, clinics, and other healthcare settings.
The topoisomerase I inhibitors market consists of sales of chemotherapy drugs, diagnostic kits, intravenous infusion bags and combination therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Topoisomerase I Inhibitors Market Characteristics
3. Topoisomerase I Inhibitors Market Supply Chain Analysis
4. Global Topoisomerase I Inhibitors Market Trends and Strategies
5. Topoisomerase I Inhibitors Market Analysis of End Use Industries
7. Global Topoisomerase I Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Topoisomerase I Inhibitors Total Addressable Market (TAM) Analysis for the Market
9. Topoisomerase I Inhibitors Market Segmentation
10. Topoisomerase I Inhibitors Market Regional and Country Analysis
11. Asia-Pacific Topoisomerase I Inhibitors Market
12. China Topoisomerase I Inhibitors Market
13. India Topoisomerase I Inhibitors Market
14. Japan Topoisomerase I Inhibitors Market
15. Australia Topoisomerase I Inhibitors Market
16. Indonesia Topoisomerase I Inhibitors Market
17. South Korea Topoisomerase I Inhibitors Market
18. Taiwan Topoisomerase I Inhibitors Market
19. South East Asia Topoisomerase I Inhibitors Market
20. Western Europe Topoisomerase I Inhibitors Market
21. UK Topoisomerase I Inhibitors Market
22. Germany Topoisomerase I Inhibitors Market
23. France Topoisomerase I Inhibitors Market
24. Italy Topoisomerase I Inhibitors Market
25. Spain Topoisomerase I Inhibitors Market
26. Eastern Europe Topoisomerase I Inhibitors Market
27. Russia Topoisomerase I Inhibitors Market
28. North America Topoisomerase I Inhibitors Market
29. USA Topoisomerase I Inhibitors Market
30. Canada Topoisomerase I Inhibitors Market
31. South America Topoisomerase I Inhibitors Market
32. Brazil Topoisomerase I Inhibitors Market
33. Middle East Topoisomerase I Inhibitors Market
34. Africa Topoisomerase I Inhibitors Market
36. Topoisomerase I Inhibitors Market Competitive Landscape and Company Profiles
37. Topoisomerase I Inhibitors Market Other Major and Innovative Companies
40. Topoisomerase I Inhibitors Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Topoisomerase I Inhibitors Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses topoisomerase i inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for topoisomerase i inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The topoisomerase i inhibitors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Camptothecin Derivatives; Non-Camptothecin2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
3) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Camptothecin Derivatives: Irinotecan; Topotecan2) By Non-Camptothecin: LMP-400; Indenoisoquinolines
Companies Mentioned: Pfizer Inc; AstraZeneca PLC; Novartis AG; Merck KGaA; Daiichi Sankyo Company Limited; Ipsen Pharma SAS; Fresenius Kabi AG; Debiopharm Group SA; Sigma Tau Industrie Farmaceutiche Riunite SPA; Sagent Pharmaceuticals Inc; Gibson Oncology LLC; TopoGEN Inc; DualityBio Inc; Iksuda Therapeutics Ltd; Nektar Therapeutics; Exelixis Inc; BeiGene Ltd; Takeda Pharmaceutical Company Limited; Amgen Inc; Hutchmed China Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Topoisomerase I Inhibitors market report include:- Pfizer Inc
- AstraZeneca PLC
- Novartis AG
- Merck KGaA
- Daiichi Sankyo Company Limited
- Ipsen Pharma SAS
- Fresenius Kabi AG
- Debiopharm Group SA
- Sigma Tau Industrie Farmaceutiche Riunite SPA
- Sagent Pharmaceuticals Inc
- Gibson Oncology LLC
- TopoGEN Inc
- DualityBio Inc
- Iksuda Therapeutics Ltd
- Nektar Therapeutics
- Exelixis Inc
- BeiGene Ltd
- Takeda Pharmaceutical Company Limited
- Amgen Inc
- Hutchmed China Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.79 Billion |
| Forecasted Market Value ( USD | $ 7.31 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
